Policosanol
12 benefits mapped to clinical evidence across supplements.
Dose per serving from products
256 products in our catalogue print how much Policosanol a serving holds.
Most common: 5 mg to 10 mg, 64% of 256 products.
| Dose per serving | Products |
|---|---|
| 2.5 mg or less | 3 |
| 2.5 mg to 5 mg | 20 |
| 5 mg to 10 mg | 165 |
| 10 mg to 25 mg | 48 |
| 25 mg to 50 mg | 12 |
| over 50 mg | 8 |
Dose per serving from research
63 study groups in 45 studies say how much Policosanol participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 52% of 63 study groups.
| Daily dose | Study groups |
|---|---|
| 2.5 mg or less | 1 |
| 2.5 mg to 5 mg | 6 |
| 5 mg to 10 mg | 33 |
| 10 mg to 25 mg | 19 |
| 25 mg to 50 mg | 4 |
Commonly used together
13 of 63 study groups took Policosanol with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Red Yeast Rice | 9 |
| Berberine | 8 |
| Coenzyme Q10 | 4 |
| Folic Acid | 4 |
| Astaxanthin | 3 |
Benefit Evidence
Research sources
Cholesterol (32)
- Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk
PubMed ID: 11253161
179 older hypercholesterolemic patients: substantial LDL/TC reductions and large HDL increases.
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
PubMed ID: 22998978
Large nutraceutical pill (berberine+RYY+policosanol) produced big LDL decreases, but policosanol likely not the main driver.
- Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study
PubMed ID: 23266743
Multi-component plant supplement including policosanol lowered LDL vs placebo; policosanol's independent contribution unclear.
- [A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia]
PubMed ID: 16583932
Rice policosanol 10 mg lowered total cholesterol and raised Apo A‑I but did not change LDL—partial lipid impact.
- Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia
PubMed ID: 16050054
Notable LDL/TC reductions and HDL increases were seen, but policosanol was given with omega-3 (confounding).
- A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study
PubMed ID: 16444910
Dose-related modest LDL reductions (>=15% in many subjects) and HDL increases reported, albeit less than comparator.
- Concomitant use of policosanol and beta-blockers in older patients
PubMed ID: 15689053
Three-year randomized elderly study showed large, durable LDL reductions and HDL increases—strong direct evidence for lipid benefits.
- Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia
PubMed ID: 12534315
Elderly study showed ~23% LDL lowering and modest HDL rise.
- Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia
PubMed ID: 12099160
Large trial (n=589) demonstrating substantial LDL/TC lowering and HDL rise.
- Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women
PubMed ID: 11708573
Postmenopausal study (n=56) showing clear LDL/TC reductions and modest HDL increase.
- Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study
PubMed ID: 11708574
Dose-comparison RCT showing robust LDL reductions (~27–28%) and HDL increases.
- Effects of policosanol on postmenopausal women with type II hypercholesterolemia
PubMed ID: 10923280
Well-powered RCT in postmenopausal women showing large, dose-related LDL and HDL improvements.
- [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]
PubMed ID: 10436712
RCT reporting ~24% LDL reduction and HDL increase comparable to some statins.
- A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia
PubMed ID: 10645516
Smaller RCT reporting total cholesterol decrease and good tolerability versus acipimox.
- Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
PubMed ID: 10223782
Large RCT (n=437) with clear, clinically meaningful LDL reductions and HDL increases.
- Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
PubMed ID: 10939029
Diabetic RCT where policosanol reduced LDL/TC and raised HDL versus lovastatin.
- A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
PubMed ID: 8871266
Two-year RCT showing sustained LDL/TC reductions and HDL increases.
- Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia
PubMed ID: 12503776
110-patient RCT with clear dose-dependent LDL/TC reductions and HDL increases.
- A randomized, double-blind, placebo-controlled trial to evaluate efficacy and tolerability of an optimized botanical combination in the management of patients with primary hypercholesterolemia and mixed dyslipidemia
PubMed ID: 21674629
Botanical mix with policosanol lowered LDL and TC in RCT (small sample; multiple botanicals).
- A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO(®)) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study)
PubMed ID: 33066334
8‑week RCT of combined nutraceutical (includes policosanol) produced large LDL, TC and apoB reductions vs placebo.
- The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk
PubMed ID: 29951651
Short (1‑month) controlled trial of a monacolin‑rich nutraceutical containing policosanol produced marked LDL/TC reductions.
- A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial
PubMed ID: 31371114
Armolipid Plus reduced LDL and total cholesterol and also decreased left ventricular mass in metabolic syndrome patients.
- Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)
PubMed ID: 28781026
Adding Armolipid Plus to low‑dose statin produced substantial incremental LDL lowering in high‑risk patients.
- Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease
PubMed ID: 26611120
In statin‑intolerant coronary patients, Armolipid Plus (contains policosanol) improved LDL target attainment vs ezetimibe (multi‑component).
- Multiple functions of policosanol in elderly patients with dyslipidemia
PubMed ID: 32703038
Elderly dyslipidemic cohort showed LDL decreases with policosanol in pragmatic settings (mixed designs).
- Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
PubMed ID: 30885221
Armolipid Plus improved LDL, total cholesterol and sdLDL properties over 24 weeks (multi‑ingredient).
- Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study
PubMed ID: 30841655
Dose‑response RCT in prehypertensive adults showed clinically meaningful LDL reductions with policosanol monotherapy.
- Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study
PubMed ID: 30286820
Elderly dyslipidemic patients had LDL/non‑HDL/TC decreases with policosanol (alone and combined) in randomized setting.
- [Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia]
PubMed ID: 24113041
Policosanol added to simvastatin produced larger LDL and TC reductions vs simvastatin+placebo (RCT), though confounded by combination therapy.
- Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus
PubMed ID: 24528686
Armolipid Plus (multi-ingredient including policosanol) lowered LDL comparably to low-dose pravastatin; role of policosanol uncertain.
- A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial
PubMed ID: 23815518
Combined supplement including policosanol reduced LDL and ApoB in untreated hypercholesterolemics; attribution uncertain.
- [Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia]
PubMed ID: 23302671
Policosanol 20 mg/day lowered total cholesterol in hyperlipidemic patients in an open randomized trial.
Heart health (20)
- A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
PubMed ID: 10063942
Clinically meaningful functional improvements in peripheral arterial disease support cardiovascular wellbeing.
- A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial
PubMed ID: 31371114
Reduction in left ventricular mass plus improved lipids in metabolic syndrome patients supports cardiac‑structure and risk benefits.
- Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study
PubMed ID: 41032504
Multicenter RCT in hypertensives with robust BP and LDL improvements supports cardiovascular wellness.
- Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study
PubMed ID: 40189869
Large randomized monotherapy trial showed clinically meaningful BP and LDL reductions—strong overall cardiovascular benefit.
- Multiple functions of policosanol in elderly patients with dyslipidemia
PubMed ID: 32703038
Multiple favorable vascular and inflammatory marker changes in elderly dyslipidemic patients support CV wellness.
- Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
PubMed ID: 30885221
Armolipid Plus improved LDL and atherogenic LDL properties in metabolic syndrome, benefiting cardiovascular risk profile.
- Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study
PubMed ID: 30841655
Dose‑dependent BP and lipid improvements in prehypertensive adults are directly cardiovascular‑relevant.
- Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study
PubMed ID: 30286820
Lipid improvements and reduced arterial stiffness in elderly are favorable for cardiovascular wellness.
- Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results
PubMed ID: 27328023
Reduction of platelet reactivity after stenting and fewer minor bleeds demonstrates clinically relevant cardiovascular protection.
- [Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia]
PubMed ID: 24113041
Add‑on to simvastatin produced larger LDL/TC drops which are favorable for cardiovascular health (combination confounded).
- [Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia]
PubMed ID: 23302671
Total-cholesterol reduction and HO-1 decrease could reflect cardiovascular wellness, albeit in an open-label trial.
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
LDL reduction and modest FMD improvement with a multi-ingredient product suggest cardiovascular benefit but policosanol not isolated.
- A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study
PubMed ID: 16444910
Modest dose-related lipid improvements imply some heart-health relevance though effects were moderate.
- Concomitant use of policosanol and beta-blockers in older patients
PubMed ID: 15689053
Durable lipid improvements, HDL rise, BP lowering and good tolerability over 3 years indicate broad cardiovascular wellness benefits.
- Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia
PubMed ID: 12099160
Large, long study showing lipid improvements, HDL rise, fewer vascular SAEs and BP lowering—broad cardiovascular benefit.
- Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk
PubMed ID: 11253161
Older hypercholesterolemic cohort showed major lipid benefits and improved cardiovascular capacity.
- Effects of policosanol on postmenopausal women with type II hypercholesterolemia
PubMed ID: 10923280
Postmenopausal RCT with meaningful LDL/HDL/TC changes and good safety, relevant to heart disease risk.
- Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
PubMed ID: 10223782
Large RCT with robust LDL reduction, HDL rise and good tolerability—key for cardiovascular risk reduction.
- Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
PubMed ID: 9760006
Clinical CHD outcomes: improved exercise responses and fewer ischemic events when used long-term (clinical cardiovascular signals).
- Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers
PubMed ID: 9425618
Strong antiplatelet effects (comparable/additive to aspirin) reduce thrombotic risk component of cardiovascular disease.
Wellbeing (8)
- Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese
PubMed ID: 36982259
12-week RCT with multiple favorable changes (BP/HDL/HbA1c) that could support general wellness.
- A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
PubMed ID: 8871266
Two-year maintenance study demonstrating sustained lipid improvements and good tolerability over long term.
- Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
PubMed ID: 10223782
Large RCT showing durable lipid benefits and safety supportive of long-term wellness maintenance.
- Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia
PubMed ID: 12099160
Large trial with sustained lipid, BP and SAE reductions consistent with maintenance of cardiovascular wellness.
- Concomitant use of policosanol and beta-blockers in older patients
PubMed ID: 15689053
Long-term safety/tolerability plus sustained cardiometabolic improvements in elderly support general wellness maintenance.
- Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results
PubMed ID: 27328023
Reduced platelet reactivity with fewer minor bleeds in post‑stent patients is clinically valuable for ongoing cardiovascular maintenance.
- Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study
PubMed ID: 40189869
Large RCT showing BP and LDL improvements with good tolerability supports general wellness maintenance in prehypertensives.
- Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study
PubMed ID: 41032504
Robust BP and LDL reductions with policosanol in hypertensive patients and good tolerability support maintenance of health.
Blood circulation (10)
- Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results
PubMed ID: 27328023
Demonstrated reduced platelet reactivity after stenting, directly supporting improved patency/flow and lower thrombotic risk.
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
Endothelial function (FMD) improved with a multi-ingredient product including policosanol—suggesting better blood flow though not isolated.
- Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study
PubMed ID: 18388038
Improved walking distance vs aspirin supports a circulation benefit in symptomatic PAD patients (small study).
- A long-term study of policosanol in the treatment of intermittent claudication
PubMed ID: 11228084
Two-year claudication trial reported improved walking distance and ankle/arm index, consistent with better circulation.
- A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
PubMed ID: 10063942
Marked increases in walking distance in claudication patients imply improved peripheral blood flow/tolerance.
- Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers
PubMed ID: 9425618
Large reductions in platelet aggregation (multiple agonists) support improved rheology and reduced microthrombotic risk.
- Multiple functions of policosanol in elderly patients with dyslipidemia
PubMed ID: 32703038
Large elderly cohort showed lower platelet aggregation and fewer circulating endothelial cells, consistent with better vascular health/flow.
- Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
PubMed ID: 9076841
Dose-dependent platelet aggregation inhibition in healthy volunteers supports improved blood flow potential.
- Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study
PubMed ID: 30841655
BP and HDL/LDL improvements in prehypertensives support healthier vascular dynamics.
- Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study
PubMed ID: 30286820
Improvements in arterial stiffness (ba‑PWV) indicate better arterial compliance and likely improved flow.
Blood pressure (6)
- Concomitant use of policosanol and beta-blockers in older patients
PubMed ID: 15689053
Study reported BP lowering in elderly beta‑blocker users over long-term policosanol treatment.
- Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study
PubMed ID: 41032504
Multicenter randomized trial in grade I hypertensives showed substantial SBP reductions (~−14 mmHg) with policosanol monotherapy.
- Short-Term Consumption of Cuban Policosanol Lowers Aortic and Peripheral Blood Pressure and Ameliorates Serum Lipid Parameters in Healthy Korean Participants: Randomized, Double-Blinded, and Placebo-Controlled Study
PubMed ID: 30841655
Randomized placebo study in prehypertensive adults showed dose‑dependent central/peripheral BP lowering with policosanol.
- Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study
PubMed ID: 40189869
Large randomized Cuban trial: policosanol 20 mg/day significantly lowered SBP/DBP vs placebo (monotherapy).
- Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese
PubMed ID: 36982259
12-week RCT in healthy adults showed a significant systolic BP reduction (~7.1%).
- Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia
PubMed ID: 12099160
Large trial in older hypertensive hypercholesterolemic patients reported systolic BP decreases (trial-level effect).
Healthy aging (5)
- Multiple functions of policosanol in elderly patients with dyslipidemia
PubMed ID: 32703038
Large elderly cohort had improved vascular/inflammatory markers with policosanol or atorvastatin, relevant to healthy aging.
- Efficacy and Safety of Policosanol Plus Fenofibrate Combination Therapy in Elderly Patients with Mixed Dyslipidemia: A Randomized, Controlled Clinical Study
PubMed ID: 30286820
Elderly randomized trial showed lipid improvements and reduced arterial stiffness with policosanol.
- [Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study]
PubMed ID: 28169410
Improved post‑stroke functional outcomes support maintenance of function during aging (secondary implication).
- Concomitant use of policosanol and beta-blockers in older patients
PubMed ID: 15689053
Three-year elderly study showing durable lipid and BP improvements and good tolerability suggests relevance to healthy aging.
- Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients
PubMed ID: 30350844
Marked functional recovery in hypertensive stroke patients implies benefits relevant to aging populations' function.
Endurance (6)
- A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
PubMed ID: 10063942
Large increases in initial and absolute claudication distances directly reflect improved endurance.
- A long-term study of policosanol in the treatment of intermittent claudication
PubMed ID: 11228084
Two-year claudication study showed sustained walking-distance improvements consistent with enhanced stamina.
- Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
PubMed ID: 9760006
Improvements in VO2max and exercise tolerance in CHD patients indicate enhanced endurance.
- Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients
PubMed ID: 30350844
Substantial functional recovery in hypertensive stroke subgroup implies improved activity endurance; direct endurance testing not reported.
- [Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study]
PubMed ID: 28169410
Improved mobility/function after stroke suggests better functional endurance in daily activities, though not exercise endurance per se.
- Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study
PubMed ID: 18388038
Short-term improvement in walking distance vs aspirin suggests endurance benefit (limited by trial size/duration).
Exercise recovery (6)
- Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study
PubMed ID: 18388038
Short-term randomized trial showed increased walking distance vs aspirin, supporting improved exercise recovery (small sample/duration).
- A long-term study of policosanol in the treatment of intermittent claudication
PubMed ID: 11228084
Two-year claudication study documented sustained improvements in walking distance and functional status.
- A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
PubMed ID: 10063942
Claudiation trial produced large increases in walking distance, implying improved post-exertion recovery/tolerance.
- Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
PubMed ID: 9760006
Long-term CHD trial showed improved exercise-ECG responses and increased VO2max (functional recovery after exertion).
- Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients
PubMed ID: 30350844
Subgroup stroke trial (hypertensive patients) showed marked functional recovery with policosanol+aspirin vs aspirin alone.
- [Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study]
PubMed ID: 28169410
Policosanol+aspirin after ischemic stroke produced large functional/mobility gains vs aspirin alone (direct recovery outcome).
Vitality (5)
- Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
PubMed ID: 9760006
Improved functional capacity/VO2max in CHD patients suggests better overall physical vitality.
- A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
PubMed ID: 10063942
Marked improvements in walking distance and symptoms in claudication imply improved day-to-day vitality.
- Concomitant use of policosanol and beta-blockers in older patients
PubMed ID: 15689053
Long-term tolerability with sustained lipid and BP improvements in elderly may contribute to overall vitality in that population.
- [Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study]
PubMed ID: 28169410
Marked functional gains after stroke imply improved day‑to‑day vitality in treated patients.
- Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients
PubMed ID: 30350844
Large functional recovery in hypertensive stroke subgroup supports improved overall vitality.
Antioxidant (3)
- Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese
PubMed ID: 36982259
Improved HDL functionality in Japanese adults suggests enhanced anti-oxidative HDL actions.
- Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus
PubMed ID: 12837046
Diabetic dyslipidemic trial showed increased LDL oxidation lag time (improved LDL resistance to oxidation).
- A randomized, double-blind, placebo-controlled trial to evaluate efficacy and tolerability of an optimized botanical combination in the management of patients with primary hypercholesterolemia and mixed dyslipidemia
PubMed ID: 21674629
Trial of botanical combination including policosanol showed reductions in oxidative stress markers (MDA/CRP reported).
Energy & Fatigue (2)
- Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
PubMed ID: 9760006
VO2max and exercise performance gains indicate increased physiological energy/functional capacity.
- A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
PubMed ID: 10063942
Substantial increases in walking distance consistent with greater exercise-derived energy/endurance.
Metabolism (1)
- Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese
PubMed ID: 36982259
Reported modest HbA1c reduction and HDL improvements (metabolic parameter benefits).
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Policosanol
Search all317 products whose verified label declares Policosanol — not every bottle that mentions it in a title.